I mentioned a couple of weeks ago, that due to the loss of my "<" and 2 PSA tests coming back at .02 (i know, i know, its low, measurable but not detectable)
, my Uro/Surgeon was having a proprietary genomic test done on my prostate tissue removed at surgery. Not as good as Decipher, but still good info to have.
It looks like the test came back saying i am at low risk for recurrence, but its all gobbledegook to me. Figured I'd copy and paste is, maybe some of our resident geniuses can shed some light?...i won't see the Dr till May, but i might call the PA to see if i can get a more detailed explanation....
Precise MD -- Immunohistochemical Panel Prostate
Staining Staining
Antibody Frequency Intensity RESULTS
AR 70% 2-3+ POSITIVE
ERG 70% 3+ DIFFUSE OVEREXPRESSION
p53 1.0% 1+ NEGATIVE
ki-67 3.3% 3+ LOW PROLIFERATION
INTERPRETATION:
The moderately diffuse, moderate to high Androgen Receptor (AR;
2-3+, 70%) and low Ki67 (proliferative index: 3.3%) would suggest
that the patient is at low risk for disease progression.
In addition, the diffuse overexpression of ERG protein supports
the presence of the ERG rearrangement. The lack of p53 protein
supports the absence of a TP53 mutation.
1. Donovan et al., Personalized prediction of tumor response and
cancer progression on prosta
te needle biopsy. J Urol 2009;
182:125-32, 2. Svensson et al., A comparative study of ERG status
assessment on DNA, mRNA, and protein levels using unique samples
from a Swedish biopsy cohort. Appl Immunohistochem Mol Morphol
2014; 22:136-41.3). Kluth et al., Clinical significance of
different types of p53 gene alteration in surgically treated
prostate cancer. Int J Cancer 2014.
COMMENTS-
AR Negative < 1%, Weak Positive 1 - 10%, Positive > 10%
ERG Negative = <1%, Focal Overexpression 1 - 25%, Diffuse
Overexpression > 25%
p53 Negative < 5%, Borderline 5 - 10%, Positive >10 - 50%, Strong
Positive > 50%
Ki-67 High/Low Cutoff = 6.0% (Mayo Clin Proc
2014;89(3);308-318)
Block Examined- ms-15-314 A1
TECHNICAL NOTES-
For each antibody, a minimum of 500 tumor cells were counted.
All immunostains were performed on formalin-fixed,
paraffin-embedded tissue with appropriate controls on Ventana
Benchmark Ultra.
AR clone SP107, Rabbit monoclonal
ERG clone EPR3864,
Rabbit monoclonal
p53 clone DO-7, Mouse monoclonal
ki-67 clone 30-9, Rabbit monoclonal
This test or one or more of its components was developed and its
performance characteristics determined by the Mount Sinai Clinical
Laboratories. It has not been cleared or approved by the US food
and Drug Administration. The FDA has determined that such
clearance or approval is not necessary.
G. Kenneth Haines III, MD
Attending Pathologist
GROSS DEscriptION:
Immunostains performed on ms-15-314 block A1.
The following statement applies to Histochemical,
Immunohistochemical, Immunofluorescence, In Situ Hybridization
(ISH or FISH), and/or molecular test(s) associated with this
report: The test has not been cleared or approved for the
specific use by the U.S. Food and Drug Administration. FDA does
not require this test to go through premarket FDA review. This
test is used for clinical purposes. It should not be regarded as
investigational or for research. This laboratory i
s certified
under the Clinical Laboratory Improvement Amendments 1988 (CLIA)
as qualified to perform high complexity clinical laboratory
testing. All stains and tests are performed with appropriate
positive and negative control reactions and all controls show
appropriate reactivity. However, stains and tests have not been
validated on decalcified tissues. Results should be interpreted
with caution given the likelihood of false negativity on
decalcified specimens. Certain tests utilize Class I
Analyte-Specific Reagents (ASR); these tests are developed and
their performance characteristics determined by this laboratory.
ASRs used in this laboratory have been established and verified
for accuracy and precision. Additional information about this
type of test is available upon request.
The electronic signature(s) indicates that the named Attending
Pathologist has evaluated the specimen referred to in the signed
section of the report and formulated the diagnosis there
in.
Final Diagnosis performed by
G. KENNETH HAINES III, MD
Electronically signed 2/17/2017 5:59:41PM Post Edited (Pratoman) : 2/21/2017 12:51:17 PM (GMT-7)